Bacillus licheniformis L-arabinose isomerase (L-AI) is distinguished from other L-AIs by its high degree of substrate specificity for L-arabinose and its high turnover rate. A systematic strategy that included a sequence alignment-based first screening of residues and a homology model-based second screening, followed by site-directed mutagenesis to alter individual screened residues, was used to study the molecular determinants for the catalytic efficiency of B. licheniformis L-AI. One conserved amino acid, Y333, in the substrate binding pocket of the wild-type B. licheniformis L-AI was identified as an important residue affecting the catalytic efficiency of B. licheniformis L-AI. Further insights into the function of residue Y333 were obtained by replacing it with other aromatic, nonpolar hydrophobic amino acids or polar amino acids. Replacing Y333 with the aromatic amino acid Phe did not alter catalytic efficiency toward L-arabinose. In contrast, the activities of mutants containing a hydrophobic amino acid (Ala, Val, or Leu) at position 333 decreased as the size of the hydrophobic side chain of the amino acid decreased. However, mutants containing hydrophilic and charged amino acids, such as Asp, Glu, and Lys, showed almost no activity with L-arabinose. These data and a molecular dynamics simulation suggest that Y333 is involved in the catalytic efficiency of B. licheniformis L-AI.
L-Arabinose isomerase (L-AI) is an enzyme that mediates in vivo isomerization between L-arabinose and L-ribulose as well as in vitro isomerization of D-galactose and D-tagatose (20).L-Ribulose (L-erythro-pentulose) is a rare and expensive ketopentose sugar (1) that can be used as a precursor for the production of other rare sugars of high market value, such as L-ribose. Despite being a common metabolic intermediate in different organisms, L-ribulose is scarce in nature. The market for rare and unnatural sugars has been growing, especially in the sweetener and pharmaceutical industries. For example, several modified nucleosides derived from L-sugars have been shown to act as potent antiviral agents and are also useful in antigen therapy. Derivatives of rare sugars have also been used as agents against hepatitis B virus and human immunodeficiency virus (2,22).For these reasons, interest in the enzymology of rare sugars has also been increasing. Various forms of L-AI from a variety of organisms have been characterized, and some have shown potential for industrial use. Several highly thermotolerant enzyme forms from Thermotoga maritima (12), Thermotoga neapolitana (10), Bacillus stearothermophilus (18), Thermoanaerobacter mathranii (9), and Lactobacillus plantarum (5) have been characterized previously. All of these reported L-AIs tend to have broad specificity, although a few L-AIs with high degrees of substrate specificity for L-arabinose have also been documented.The enzyme properties of L-AIs have been examined by engineering several forms by error-prone PCR and site-directed mutagenesis. Galactose conversion was reportedly enhance...